Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report) shares fell 4% during mid-day trading on Thursday . The stock traded as low as $16.81 and last traded at $16.85. 73,147 shares changed hands during mid-day trading, a decline of 61% from the average session volume of 186,510 shares. The stock had previously closed at $17.56.
Analysts Set New Price Targets
Separately, Wall Street Zen raised Pulse Biosciences to a "sell" rating in a research note on Monday, March 31st.
Read Our Latest Research Report on Pulse Biosciences
Pulse Biosciences Price Performance
The company has a 50 day simple moving average of $16.85 and a 200-day simple moving average of $17.98.
Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.25) earnings per share for the quarter.
Institutional Trading of Pulse Biosciences
A number of institutional investors have recently made changes to their positions in PLSE. Vanguard Group Inc. raised its holdings in shares of Pulse Biosciences by 15.1% during the fourth quarter. Vanguard Group Inc. now owns 1,146,339 shares of the company's stock valued at $19,958,000 after acquiring an additional 150,506 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Pulse Biosciences by 0.4% during the fourth quarter. Bank of America Corp DE now owns 788,454 shares of the company's stock valued at $13,727,000 after acquiring an additional 2,884 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Pulse Biosciences by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 460,768 shares of the company's stock valued at $8,024,000 after acquiring an additional 3,603 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Pulse Biosciences by 1,956.7% during the fourth quarter. Invesco Ltd. now owns 214,490 shares of the company's stock valued at $3,734,000 after acquiring an additional 204,061 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Pulse Biosciences by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 149,206 shares of the company's stock valued at $2,598,000 after acquiring an additional 1,092 shares in the last quarter. Hedge funds and other institutional investors own 76.95% of the company's stock.
Pulse Biosciences Company Profile
(
Get Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Featured Articles
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
